Takeda Pharmaceuticals U.S.A., Inc. announced today that in the case of Bertha Triana and Delores Cipriano v. Takeda, et al., No. A680556 the jury found in favor of Takeda. The trial began on March 10 in Nevada state court before Judge Kerry Earley.
“We agree with the verdict, which is in favor of Takeda,” said Kenneth D. Greisman, senior vice president, general counsel, Takeda Pharmaceuticals U.S.A., Inc. “Takeda is confident in the therapeutic benefits of ACTOS and its importance as a treatment for type 2 diabetes and we will continue to defend the company vigorously in these cases.” Today’s verdict marks the fifth win for Takeda out of six ACTOS (pioglitazone HCL) trials. Takeda is challenging the ruling in the sixth case.
“Patient safety is a critical priority for Takeda,” said Greisman. “We have empathy for Ms. Triana and Ms. Cipriano, but we believe we have acted responsibly with regard to ACTOS.”
